H.C. Wainwright reiterated a Buy rating for Marker Therapeutics with a $10.00 price target. Management expects a single-arm Phase 2 trial could support regulatory registration for its post-CAR-T DLBCL treatment. This clinical path relies on the current lack of a standard of care for the target indication.
The company reported $15.6 million in cash and cash equivalents at the end of the first quarter of 2026. Operating cash use totaled $1.4 million for the quarter. While clinical development costs preclude profitability this year, the current financial position supports ongoing trial advancement.